JP2012131811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012131811A5 JP2012131811A5 JP2012034259A JP2012034259A JP2012131811A5 JP 2012131811 A5 JP2012131811 A5 JP 2012131811A5 JP 2012034259 A JP2012034259 A JP 2012034259A JP 2012034259 A JP2012034259 A JP 2012034259A JP 2012131811 A5 JP2012131811 A5 JP 2012131811A5
- Authority
- JP
- Japan
- Prior art keywords
- vomiting
- emesis
- nausea
- palonosetron
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010047700 Vomiting Diseases 0.000 description 14
- 230000008673 vomiting Effects 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 4
- 229960002131 palonosetron Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42682902P | 2002-11-15 | 2002-11-15 | |
| US60/426,829 | 2002-11-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553037A Division JP5690461B2 (ja) | 2002-11-15 | 2003-11-06 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015086840A Division JP2015143266A (ja) | 2002-11-15 | 2015-04-21 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012131811A JP2012131811A (ja) | 2012-07-12 |
| JP2012131811A5 true JP2012131811A5 (cg-RX-API-DMAC7.html) | 2014-04-17 |
| JP5893950B2 JP5893950B2 (ja) | 2016-03-23 |
Family
ID=32326433
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553037A Expired - Lifetime JP5690461B2 (ja) | 2002-11-15 | 2003-11-06 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
| JP2012034259A Expired - Lifetime JP5893950B2 (ja) | 2002-11-15 | 2012-02-20 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
| JP2015086840A Pending JP2015143266A (ja) | 2002-11-15 | 2015-04-21 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
| JP2016162972A Expired - Lifetime JP6342960B2 (ja) | 2002-11-15 | 2016-08-23 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553037A Expired - Lifetime JP5690461B2 (ja) | 2002-11-15 | 2003-11-06 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015086840A Pending JP2015143266A (ja) | 2002-11-15 | 2015-04-21 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
| JP2016162972A Expired - Lifetime JP6342960B2 (ja) | 2002-11-15 | 2016-08-23 | 化学療法誘導嘔吐を治療するためのパロノセトロン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060079545A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP5690461B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003302072A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2505990C (cg-RX-API-DMAC7.html) |
| DE (1) | DE10393729T5 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004045615A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340484T3 (es) * | 2002-11-05 | 2010-06-04 | Glaxo Group Limited | Agentes antibacterianos. |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
| PT1940366E (pt) | 2006-10-24 | 2009-06-17 | Helsinn Healthcare Sa | Cápsulas moles compreendendo cloridrato de palonossetrom possuindo estabilidade e disponibilidade biológica melhoradas |
| WO2008073757A1 (en) * | 2006-12-07 | 2008-06-19 | Helsinn Healthcare Sa | Crystalline and amorphous forms of palonosetron hydrochloride |
| ES2527448T3 (es) * | 2008-04-28 | 2015-01-23 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
| EP2286814B1 (en) | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| WO2010077669A2 (en) * | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
| WO2011058427A1 (en) | 2009-11-13 | 2011-05-19 | Helsinn Healthcare S.A. | Palonosetron metabolites |
| RS55206B1 (sr) | 2009-11-18 | 2017-01-31 | Helsinn Healthcare Sa | Kompozicije za lečenje centralno posredovane mučnine i povraćanja |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| US20160206610A1 (en) * | 2015-01-20 | 2016-07-21 | Xoc Pharmaceuticals, Inc. | Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis |
| JP6642377B2 (ja) * | 2016-10-25 | 2020-02-05 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US807381A (en) * | 1905-01-10 | 1905-12-12 | Auto Stopper Company | Means for securing stoppers for vessels in their caps. |
| US1796729A (en) * | 1930-04-18 | 1931-03-17 | Aluminum Co Of America | Closure |
| US2069075A (en) * | 1934-04-20 | 1937-01-26 | United Dairies London Ltd | Bottle or like container |
| US2113176A (en) * | 1936-03-26 | 1938-04-05 | Guardian Safety Seal Company | Sealed receptacle |
| US3314564A (en) * | 1965-05-06 | 1967-04-18 | West Co | Container closure |
| US3601273A (en) * | 1969-01-31 | 1971-08-24 | Aluminum Co Of America | Pilferproof closure with vertical weakening lines |
| DE2315962A1 (de) * | 1972-04-05 | 1973-10-18 | Metal Closures Ltd | Verschlusskappenrohling fuer flaschen od. dgl. |
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| DE3650772T2 (de) * | 1985-04-27 | 2003-04-03 | F. Hoffmann-La Roche Ag, Basel | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
| US4937247A (en) * | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| US5240954A (en) * | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| US5578628A (en) * | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
| US4906755A (en) * | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
| US5011846A (en) * | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
| US5344658A (en) * | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| KR970007917B1 (ko) * | 1989-11-28 | 1997-05-17 | 신텍스 인크. | 신규 삼환식 화합물 |
| GB2277749B (en) * | 1993-05-08 | 1996-12-04 | Ciba Geigy Ag | Fluorescent whitening of paper |
| GB9423588D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| GB9423511D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| US6294548B1 (en) * | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
| US20030127420A1 (en) * | 2002-01-09 | 2003-07-10 | Klaus Schumacher | Dual bottle closure |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
-
2003
- 2003-11-06 AU AU2003302072A patent/AU2003302072A1/en not_active Abandoned
- 2003-11-06 CA CA002505990A patent/CA2505990C/en not_active Expired - Lifetime
- 2003-11-06 WO PCT/IB2003/005567 patent/WO2004045615A1/en not_active Ceased
- 2003-11-06 JP JP2004553037A patent/JP5690461B2/ja not_active Expired - Lifetime
- 2003-11-06 DE DE10393729T patent/DE10393729T5/de not_active Withdrawn
-
2005
- 2005-05-16 US US11/129,839 patent/US20060079545A1/en not_active Abandoned
-
2011
- 2011-03-31 US US13/077,374 patent/US20110178118A1/en not_active Abandoned
-
2012
- 2012-02-20 JP JP2012034259A patent/JP5893950B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-21 JP JP2015086840A patent/JP2015143266A/ja active Pending
-
2016
- 2016-08-23 JP JP2016162972A patent/JP6342960B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012131811A5 (cg-RX-API-DMAC7.html) | ||
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| SA522432668B1 (ar) | طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2019511496A5 (cg-RX-API-DMAC7.html) | ||
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| MX2022005596A (es) | Regimen de dosificacion para agentes anti-dll3. | |
| JP2016509050A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530706A5 (cg-RX-API-DMAC7.html) | ||
| MX389336B (es) | Formulacion farmaceutica. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| JP2018506533A5 (cg-RX-API-DMAC7.html) | ||
| AR088453A1 (es) | Regimen de dosificacion del agonista o modulador del receptor de s1p | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2014502608A5 (cg-RX-API-DMAC7.html) | ||
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| AR080048A1 (es) | Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| MX393290B (es) | Composicion para el tratamiento de la osteoartritis | |
| IL275091B1 (en) | Methods for treating gaucher disease | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente |